Abstract
At a recent meeting of the human subjects committee of which I am a member, we discussed a proposed protocol involving an analysis of human immunodeficiency virus (HIV) infection in pregnant women and subsequent follow-up of their offspring in rural areas of a country in sub-Saharan Africa. Recalling the recent controversy over the use of placebo in trials of zidovudine treatment to halt perinatal transmission of HIV infection in Third World countries14 and the decision by U.S. agencies to stop funding such trials,5 some members of our committee thought that the proposed protocol was ethically suspect because it did . . .